Opioid agonist treatment and risk of death or rehospitalization following injection drug use–associated bacterial and fungal infections: A cohort study in New South Wales, Australia

Thomas D. Brothers1,2,3*, Dan Lewer1,2, Nicola Jones1, Samantha Colledge-Frisby1, Michael Farrell1, Matthew Hickman4, Duncan Webster3,5, Andrew Hayward2, Louisa Degenhardt1

1 National Drug and Alcohol Research Centre (NDARC), UNSW Sydney, Sydney, Australia, 2 UCL Collaborative Centre for Inclusion Health, Institute of Epidemiology and Health Care, University College London, London, United Kingdom, 3 Department of Medicine, Dalhousie University, Halifax, Canada, 4 Population Health Sciences, University of Bristol, Bristol, United Kingdom, 5 Division of Infectious Diseases, Saint John Regional Hospital, Saint John, Canada

* thomas.brothers.20@ucl.ac.uk

Abstract

Background
Injecting-related bacterial and fungal infections are associated with significant morbidity and mortality among people who inject drugs (PWID), and they are increasing in incidence. Following hospitalization with an injecting-related infection, use of opioid agonist treatment (OAT; methadone or buprenorphine) may be associated with reduced risk of death or rehospitalization with an injecting-related infection.

Methods and findings
Data came from the Opioid Agonist Treatment Safety (OATS) study, an administrative linkage cohort including all people in New South Wales, Australia, who accessed OAT between July 1, 2001 and June 28, 2018. Included participants survived a hospitalization with injecting-related infections (i.e., skin and soft-tissue infection, sepsis/bacteremia, endocarditis, osteomyelitis, septic arthritis, or epidural/brain abscess). Outcomes were all-cause death and rehospitalization for injecting-related infections. OAT exposure was classified as time varying by days on or off treatment, following hospital discharge. We used separate Cox proportional hazards models to assess associations between each outcome and OAT exposure. The study included 8,943 participants (mean age 39 years, standard deviation [SD] 11 years; 34% women). The most common infections during participants’ index hospitalizations were skin and soft tissue (7,021; 79%), sepsis/bacteremia (1,207; 14%), and endocarditis (431; 5%). During median 6.56 years follow-up, 1,481 (17%) participants died; use of OAT was associated with lower hazard (adjusted hazard ratio [aHR] 0.63, 95% confidence interval [CI] 0.57 to 0.70). During median 3.41 years follow-up, 3,653 (41%) were rehospitalized; use of OAT was associated with lower hazard.
of these rehospitalizations (aHR 0.89, 95% CI 0.84 to 0.96). Study limitations include the use of routinely collected administrative data, which lacks information on other risk factors for injecting-related infections including injecting practices, injection stimulant use, housing status, and access to harm reduction services (e.g., needle exchange and supervised injecting sites); we also lacked information on OAT medication dosages.

**Conclusions**

Following hospitalizations with injection drug use–associated bacterial and fungal infections, use of OAT is associated with lower risks of death and recurrent injecting-related infections among people with opioid use disorder.

**Author summary**

**Why was this study done?**

- Injecting-related bacterial and fungal infections are an increasingly common cause of pain, disability, and death among people who inject drugs (PWID).
- Treatment of injecting-related infections has tended to focus on antimicrobial therapy and/or surgery, without addressing underlying substance use-related needs.
- Opioid agonist treatment (OAT; including methadone and buprenorphine) has been associated with decreased risks of other injecting-related health harms (including HIV infection, hepatitis C virus infection, and overdose death) and may be associated with reduced risks of recurrence after injecting-related infections.

**What did the researchers do and find?**

- We identified 8,943 people with opioid use disorder who were admitted to hospital with injecting-related infections in New South Wales, Australia, between 2001 and 2018.
- We found that use of OAT after hospital discharge was associated with both lower risks of death and of rehospitalization with injecting-related infections.
- Death and rehospitalization with injecting-related infections were common, even among study participants using OAT.

**What do these findings mean?**

- OAT should be considered as part of a multicomponent treatment strategy for injecting-related infections, aiming to reduce death and reinfection.
Introduction

Injection drug use–associated bacterial and fungal infections (e.g., skin and soft-tissue infections, endocarditis, osteomyelitis, septic arthritis, and epidural abscess) are associated with significant morbidity and mortality among people who inject drugs (PWID) and are costly for healthcare systems [1–6]. The incidence of hospitalization for injecting-related infections is increasing in many parts of the world, including Australia [7], Canada [2,8,9], South Africa [10], the United Kingdom [11], the United States of America [12–16], and India [17].

Prevention efforts to date have focused on individual-level behavior change interventions to promote more sterile drug preparation and safer drug injecting techniques. Unfortunately, these have shown mixed results [18–20] and have had limited impact on a population level [1]. This may be in part because of social and structural factors (e.g., criminalization, discrimination, lack of access to housing, harm reduction services, and supervised injection sites) that constrain the ability of PWID to inject more safely [1,21] and that push PWID away from healthcare [22]. Improved primary and secondary prevention approaches are urgently needed [1,13,22].

One promising potential intervention to prevent injecting-related bacterial and fungal infections is opioid agonist treatment (OAT; e.g., methadone or buprenorphine). For people with opioid use disorder, OAT is associated with many benefits including reduced risks of death and of viral infections including human immunodeficiency virus (HIV) and hepatitis C virus [23,24]. OAT limits opioid withdrawal symptoms, reduces reliance on illicit drug markets, and empowers PWID to inject less frequently or in a safer way [25,26]. Engagement in OAT is also associated with regular healthcare contacts where superficial infections may be treated before they progress and become more severe or spread through the bloodstream [22,27,28].

Despite these possible benefits, in many acute care hospitals, OAT is not prioritized as part of treatment planning during and after hospitalization with injecting-related bacterial and fungal infections [22,29–31]. This is represented in low rates of OAT prescribing for these patients in multiple studies from North America [29,31,32] and in qualitative studies from the UK [22]. Suboptimal access to OAT may reflect system-level issues that separate addiction care from specialized, acute medical care for infections [1,22,29,30]. In some hospitals, clinicians have tried to overcome this by establishing specialized addiction medicine consultation services [33–36] or by infectious diseases specialists prescribing OAT directly [29,37]. While OAT is known to be beneficial for other injecting-related health outcomes, there has been relatively little research on OAT and risk for injecting-related infections. A better understanding of how OAT affects outcomes after injecting-related infections could help inform treatment planning during and following hospitalization.

Prior analyses of potential benefits of OAT after hospitalization with injecting-related infections have been limited by small sample sizes with wide confidence intervals (CIs) [38,39]. Three administrative linkage cohort studies (all from US insurance claims data) have assessed associations between use of OAT and outcomes after hospitalization with injecting-related bacterial or fungal infections [39–41]. One study identified a reduced risk of death after hospitalizations with injecting-related endocarditis, but did not assess rehospitalizations [40]. A second study identified no significant effect (with wide CIs) on risk of rehospitalization after endocarditis and did not assess mortality [39]. A third identified a reduced risk of rehospitalization for skin and soft-tissue infections at 1 year [41]. Reflecting suboptimal access, use of OAT (or of naltrexone, an opioid antagonist medication used for opioid use disorder treatment in the US) was reported as 24% within 3 months following hospital discharge in the first
study [40] and as 6% within 30 days following discharge in the second and third studies [39,41]. The latter 2 studies also only included information on buprenorphine use, as they did not have access to insurance claims or prescribing records for methadone.

The Opioid Agonist Treatment Safety (OATS) study is an administrative data linkage cohort study in New South Wales, Australia, which includes OAT permit records (with methadone or buprenorphine) for every person accessing OAT for opioid use disorder treatment in New South Wales from 2001 to 2018 [42,43].

Using data from the OATS study, we aimed to evaluate whether use of OAT, after discharge from hospital with injecting-related bacterial and fungal infections, is associated with decreased risk of subsequent mortality or infection-related rehospitalization.

Methods
We conducted a retrospective cohort study using linked data from the OATS study, which has been described in detail elsewhere [42,43]. This manuscript follows the REporting of studies Conducted using Observational Routinely collected health Data statement for PharmacoEpidemiology (RECORD-PE) guidelines [44] (see S1 RECORD-PE checklist). Ethics approval was obtained from the NSW Population & Health Services Research Ethics Committee (2018/HRE0205), the NSW Corrective Services Ethics Committee, and the Aboriginal Health and Medical Research Council Ethics Committee (1400/18). We did not publish a protocol before conducting the analyses. The main analysis was prespecified before conducting the analyses, but the supplementary and sensitivity analyses were not prespecified.

Setting and data sources
The OATS cohort includes all patients prescribed methadone or buprenorphine for OAT in New South Wales, which is Australia’s most populous state and includes over one-third of all people receiving OAT in the country. Clinicians in NSW must apply to the state government and receive an authority to prescribe OAT for each participant. The database includes dates of OAT initiation and discontinuation. In NSW, there is no charge for OAT in public clinics or prisons. OAT may be prescribed and dispensed in specialized clinics or prescribed in primary care settings with medicine dispensed in community pharmacies.

All individuals with an OAT permit were linked to statewide hospitalization records, incarceration records, and vital statistics/death records between August 2001 and August 2018 using probabilistic linkage based on names, sex, date of birth, and Indigenous status, as described in the OATS study protocol [43].

Participants
We included OATS study participants who survived at least one emergency (unplanned) hospitalization with skin and soft-tissue infection, sepsis or bacteremia, endocarditis, osteomyelitis, septic arthritis, or central nervous system infections (brain or spine abscess), identified using ICD-10 codes (see Fig 1 for study inclusion flow diagram; see S1 Table for ICD codes). We began with codes used in prior studies [8,29,39–41] and adapted our final list based on literature review and clinical input from the investigator team.

To be eligible, these hospitalizations had to end with the participant discharged alive to the community (rather than transfer to another hospital) so that participants could be eligible for OAT outside the hospital (see Fig 1). This was so that the timing of potential exposure and potential outcome were aligned, to avoid problems with “immortal time bias” when participants would be unable to experience either the exposure (OAT outside of acute care hospitals) or the outcomes (rehospitalization or death) [45]. Eligible hospitalizations also had to be
emergency (unplanned) admissions. We excluded routine or planned admissions (e.g., for physical therapy or diagnostic procedures) because they are unlikely to represent episodes of acute illness attributable to injecting-related infections.
**Measures**

**Outcomes.** Primary outcomes were all-cause mortality and rehospitalization with an injecting-related bacterial or fungal infection. Observed time at risk (time = 0) begins the day of discharge from participants’ earliest eligible hospitalization for injecting-related infections (see Fig 2 for graphical summary of study design). Rehospitalizations for injecting-related infections were identified using the same criteria as index hospitalizations and therefore also had to be coded as emergency (unplanned) admissions. These could occur at any time point in follow-up, so may have included both hospitalizations for new infections and for failed treatments of initial infections. Participants were censored if they were still event-free on June 29, 2018.

---

**Inclusion criteria:**
- Emergency (unplanned) hospitalization for injecting-related bacterial or fungal infection

**Exclusion criteria:**
- Discharged via death or transfer to another facility

**Outcomes (Day 0 to 29 June 2018):**
- All-cause death, infection-related

**Exposure window (Day 0 to 29 June 2018):**
- Days on vs. off OAT (time-varying)

**Covariates (participant characteristics at index hospitalization):**
- Age; Sex;
- Aboriginal & Torres Strait Islander

**Covariates (participant characteristics prior to index hospitalization):**
- Prior hospitalizations related to opioid, stimulant, or alcohol use;
- Prior incarceration

**Covariates (characteristics of index hospitalization):**
- Year of hospitalization; Length of stay;
- Premature hospital discharge against medical advice;
- Comorbidity

---

**Time** | **Index date (hospital discharge)** | **End of follow-up**
--- | --- | ---

---

**Fig 2. Study design.** OAT, opioid agonist treatment.

https://doi.org/10.1371/journal.pmed.1004049.g002
**Primary exposure.** The primary exposure was use of OAT, defined by dates with an active OAT prescription. OAT exposure was treated as time varying, by day of receipt. This means that each participant’s follow-up time was divided into exposed (on OAT) and unexposed (off OAT) episodes (ie, medication status was not necessarily constant through follow-up) [46]. We did not stratify by type of OAT (i.e., methadone or buprenorphine) as we had no hypothesis that the protective effect would differ.

Consistent with previous studies, a new OAT episode was defined as one commencing 7 or more days after the end date of a prior treatment episode [47–50]. The same definition was used for defining the end of OAT episodes, treating the 6 days following the final day of the prescription as part of the episode. The decision to incorporate the 6 days following an OAT episode into the exposure definition was originally based on consultation with clinicians and pharmacologists [50]; it has been used in previous studies by members of our group [50,51], and similar cutoffs (e.g., 3 to 6 days) have been used by others [52,53]. This approach may introduce bias by allocating outcomes to the treatment period when they actually occurred after leaving treatment; this may overestimate rates of outcomes in-treatment (on OAT) and underestimate rates of outcomes out-of-treatment (off OAT), resulting in conservative estimates of potential benefit.

**Covariates.** See S1 Fig for a directed acyclic graph (DAG) describing the hypothesized relationships between OAT status, the outcomes of interest, and potential confounders. All covariates were extracted from linked hospital administrative records, unless otherwise specified.

Participant characteristics measured at the time of index hospitalization included age in years (centered to mean and standardized to units of 1 standard deviation [SD]), sex (female or not female), Indigenous status (identification as Aboriginal/Torres Strait Islander or not Indigenous), and comorbidity (defined by the count of unique ICD-10 chapters recorded in any diagnostic position for the index admission). Participant characteristics measured prior to the index hospitalization (all treated as binary) include any prior acute care hospitalizations related to poisoning or toxicity from opioids (as indicators of addiction severity; T40.0 to T40.6), alcohol (F10.0, X45, X65, Y15, T51.0), or stimulants (T40.5 T43.6), and a history of prior incarceration (which is associated with increased risk for unsafe injection practices). Dates of incarceration were derived from linked incarceration administrative records.

Characteristics of the index hospitalization include the year of admission (grouped as 2001 to 2006, 2007 to 2011, or 2012 to 2018), length of stay in days (as an indicator of initial illness severity; centered to mean and standardized to units of 1 SD), and premature patient-initiated discharge against medical advice (AMA; treated as binary). For descriptive purposes, we also classified hospitalizations by the presence of each type of injecting-related infection.

**Analysis**

All analyses were conducted using R version 3.6.3. We calculated the incidence rate (with Poisson CIs) of each outcome per person-time while exposed to OAT and per person-time while unexposed to OAT during follow-up. We then described the cumulative hazard of each outcome, by OAT exposure periods, using Kaplan–Meier curves and the Simon–Makuch extension for time-varying exposures [54]. These can be interpreted as the estimated survival for patients who did not change their OAT status during follow-up. We then used Cox proportional hazards models to estimate the association between OAT and the study outcomes to generate hazard ratios, adjusting for all covariates.

**Supplementary analyses.** The relationship between OAT use and the outcomes (mortality or rehospitalization with injecting-related infection) may vary over time and OAT may have a
larger effect closer to the time of initial hospital discharge. As such, we performed a post hoc (not prespecified) supplementary analysis to generate period-specific hazard ratios within the first year after hospital discharge, within years 2 to 3, and within years 4 to 6. We did this as an extension of our final multivariable models in the main survival analyses, adjusting for all pre-specified covariates.

**Sensitivity analyses.** We conducted several post hoc sensitivity analyses to test the robustness of our main analysis. First, we tested the impact of alternative OAT exposure period definitions. In our main analysis (described above), we prespecified that the 6 days following the end of an OAT episode is counted as part of the exposure. We tested whether we found similar results when reducing this exposure period to the 2 days following the OAT episode and when extending it to 10 days following the OAT episode.

We then conducted a sensitivity analysis to address a potential source of “immortal time bias” in the mortality outcome survival analysis. Immortal time occurs when, within an observation period, there is a period of time where an outcome event cannot possibly have occurred [45,55]. Because linkage between OAT record data and hospitalization data was retrospective, some participants may have had their initial hospitalization before their initial OAT record and would have been unable to experience death during this time (in other words, the fact that they have a future OAT record means they could not have died before then). We therefore constructed a new analytic sample only among participants who experienced hospitalization for injecting-related infection after their first record of OAT. We did not feel this potential issue with immortal time bias would affect the rehospitalization outcome survival analysis because participants could have experienced a rehospitalization event at any time (in this case, the fact that they have a future OAT record does not necessarily mean they could not have been hospitalized before then).

### Results

#### Participants

We identified 8,943 participants with at least 1 hospitalization for injecting-related bacterial or fungal infections. Characteristics of the sample are summarized in Table 1. Participants were mostly men (66.0%), and median age at study entry was 38 years. Skin and soft tissue infections were present during most hospitalizations (see Table 1), and 14% of participants experienced a premature discharge “against medical advice.” Length of stay had a right-skewed distribution, with median 4 days, 75th percentile 8 days, and 99th percentile 65 days.

Just under half of participants (4,292; 48%) were receiving OAT at the time of discharge from their index hospitalization for injecting-related infections. Of 4,651 (52%) participants without an active OAT prescription at the time of their index hospitalization, most did not access OAT soon after discharge. For example, 199 (4%) participants initiated OAT within 1 week of hospital discharge, 410 (9%) participants initiated OAT within 4 weeks, and 706 (15%) within 12 weeks.

#### Main results

**All-cause mortality.** Out of 8,943 participants, 1,481 (17%) died during follow-up. In total, participants were followed for 65,240 person-years (median 6.56 years of follow-up per person), including 34,146 (52%) person-years exposed to OAT and 31,094 (48%) person-years unexposed. Of all participants, 2,174 (24%) remained exposed to OAT throughout the entire follow-up period, and 1,341 (15%) remained unexposed throughout.

Of the deaths, 643 (43%) occurred during an OAT exposure period, and 838 (57%) occurred while unexposed to OAT. Mortality rates were 1.88 deaths (95% CI 1.17 to 2.03) per
| Variable                                      | Levels                        | Total (100%) |
|-----------------------------------------------|-------------------------------|--------------|
| Sample                                        | N (%)                         | 8,943 (100%) |
| **Participant characteristics**               |                               |              |
| Age                                           | Mean ± SD                     | 39 ± 11      |
|                                               | Median [IQR]                  | 38 [31 to 46]|
| Sex                                           | Female                        | 3,080 (34%)  |
|                                               | Male                          | 5,863 (66%)  |
| Aboriginal or Torres Strait Islander           | Yes                           | 1,321 (15%)  |
|                                               | No                            | 7,554 (85%)  |
|                                               | Unknown                       | 66 (<1%)     |
| Comorbidities¹                                | Median [IQR]                  | 3 [2 to 5]   |
| 1                                             |                               | 1,183 (13%)  |
| 2                                             |                               | 1,620 (18%)  |
| 3                                             |                               | 1,825 (20%)  |
| 4                                             |                               | 1,418 (16%)  |
| 5                                             |                               | 1,040 (12%)  |
| 6+                                            |                               | 1,857 (21%)  |
| Prior opioid-related hospitalization          | Yes                           | 749 (8%)     |
|                                               | No                            | 8,194 (92%)  |
| Prior stimulant use-related hospitalization   | Yes                           | 205 (2%)     |
|                                               | No                            | 8,738 (98%)  |
| Prior alcohol use-related hospitalization     | Yes                           | 929 (10%)    |
|                                               | No                            | 8,014 (90%)  |
| Prior experience of incarceration             | Yes                           | 3,845 (43%)  |
|                                               | No                            | 5,098 (57%)  |
| **Index hospitalization characteristics**     |                               |              |
| Year of hospitalization                       | 2001 to 2006                  | 2,772 (30%)  |
|                                               | 2007 to 2011                  | 2,412 (27%)  |
|                                               | 2012 to 2018                  | 3,809 (43%)  |
| Distribution of infections²                   | Total                         | 8,943 (100%) |
|                                               | Skin and soft tissue          | 7,021 (79%)  |
|                                               | Sepsis/bacteremia             | 1,207 (14%)  |
|                                               | Endocarditis                  | 431 (5%)     |
|                                               | Osteomyelitis                 | 375 (4%)     |
|                                               | Septic arthritis              | 323 (4%)     |
|                                               | Central nervous system        | 69 (1%)      |
| OAT prescription active at time of discharge  | Yes                           | 4,292 (48%)  |
|                                               | No                            | 4,651 (52%)  |
| Length of stay (days)                         | Mean ± SD                     | 8.9 ± 42     |
|                                               | Median [IQR]                  | 4 [2 to 8]   |
| Discharge against medical advice              | Yes                           | 1,246 (14%)  |
|                                               | No                            | 7,697 (86%)  |

¹Comorbidities defined by the number of ICD-10 chapters listed during the index hospital admission.
²Percentages sum to greater than 100% because each hospitalization may have codes for multiple infection categories.

AMA, against medical advice; IQR, interquartile range; SD, standard deviation; OAT, opioid agonist treatment.

https://doi.org/10.1371/journal.pmed.1004049.t001
100 person-years exposed to OAT and 2.69 (2.51 to 2.88) per 100 person-years unexposed to OAT.

Extended Kaplan–Meier survival curves for time to death are presented in Fig 3. Cumulative hazard for death in OAT treatment versus nontreatment periods was 0.3% versus 1.2% at 30 days, 0.8% versus 2.1% at 90 days, and 2.4% versus 4.3% at 365 days.

Results of survival models are presented in Table 2. In the adjusted model, OAT was associated with lower hazard of all-cause death (adjusted hazard ratio [aHR] 0.63, 95% CI 0.57 to 0.70).

Rehospitalization for an injecting-related infection. Out of 8,943 participants, 3,653 (41%) were rehospitalized with an injecting-related bacterial or fungal infection. The distribution of infection type for these rehospitalizations was similar to the distribution during the index hospitalization. This included 2,718 (78%) hospitalizations with skin and soft-tissue infections, 556 (15%) with sepsis, 255 (7%) with endocarditis, 254 (7%) with osteomyelitis, 144 (4%) with septic arthritis, and 53 (1%) with central nervous system infections.

Participants were followed for 44,690 person-years (median 3.41 years per participant), which included 22,987 (51%) person-years exposed to OAT and 21,703 (49%) person-years unexposed. Of all 8,943 participants, 2,693 (30%) remained exposed to OAT throughout the entire follow-up period, and 2,157 (24%) remained unexposed throughout.

Of the rehospitalizations, 1,820 (50%) occurred during an OAT exposure period, and 1,833 (50%) occurred while unexposed to OAT. Incidence rates for rehospitalization with injecting-related bacterial or fungal infection. Both analyses involve 8,943 participants. The death analysis was based on 30,667 treatment or nontreatment periods, and the rehospitalization analysis was based on 23,278 treatment or nontreatment periods. OAT, opioid agonist treatment; OATS, Opioid Agonist Treatment Safety.

https://doi.org/10.1371/journal.pmed.1004049.g003
Table 2. Results of Cox regression for survival following discharge from index hospitalization with an injecting-related bacterial or fungal infection.

| Variable                              | Levels                        | Mortality outcome  | Rehospitalization outcome¹ |
|---------------------------------------|-------------------------------|--------------------|----------------------------|
|                                       | Unadjusted hazard ratio (95% CI) | aHR (95% CI)²     | Unadjusted hazard ratio (95% CI) | aHR (95% CI)² |
|                                       |                               |                    |                            |               |
|                                       |                               |                    |                            |               |
| **Primary exposure**                  |                               |                    |                            |               |
| OAT                                   | Unexposed day                  | Ref                | Ref                         | Ref          |
|                                       | Exposed day                    | 0.72 (0.64 to 0.79) | 0.63 (0.57 to 0.70)         | 0.95 (0.89 to 1.01) | 0.89 (0.84 to 0.96) |
| **Participant characteristics**       |                               |                    |                            |               |
| Age                                   | Years (scaled)                 | 2.15 (2.04 to 2.26) | 2.04 (1.93 to 2.17)         | 1.33 (1.29 to 1.37) | 1.26 (1.12 to 1.31) |
|                                       | Male                          | Ref                | Ref                         | Ref          |
|                                       | Female                        | 0.83 (0.74 to 0.92) | 0.92 (0.82 to 1.02)         | 1.05 (0.99 to 1.13) | 1.09 (1.02 to 1.17) |
| Aboriginal or Torres Strait Islander  | No                            | Ref                | Ref                         | Ref          |
|                                       | Yes                            | 0.72 (0.61 to 0.85) | 1.02 (0.86 to 1.20)         | 0.95 (0.86 to 1.04) | 1.00 (0.91 to 1.10) |
|                                       | Unknown                        | 0.92 (0.52 to 1.62) | 0.95 (0.54 to 1.69)         | 0.57 (0.37 to 0.88) | 0.62 (0.41 to 0.96) |
| Comorbidities                         | 1                             | Ref                | Ref                         | Ref          |
|                                       | 2                             | 1.46 (1.14 to 1.89) | 1.39 (1.09 to 1.78)         | 1.14 (1.01 to 1.28) | 1.09 (0.97 to 1.23) |
|                                       | 3                             | 1.88 (1.49 to 2.38) | 1.74 (1.38 to 2.20)         | 1.15 (1.02 to 1.29) | 1.10 (0.98 to 1.24) |
|                                       | 4                             | 2.19 (1.73 to 2.79) | 1.98 (1.55 to 2.51)         | 1.29 (1.14 to 1.46) | 1.20 (1.06 to 1.36) |
|                                       | 5                             | 3.18 (2.50 to 4.05) | 2.58 (2.03 to 3.30)         | 1.54 (1.35 to 1.75) | 1.34 (1.18 to 1.54) |
|                                       | 6+                            | 5.09 (4.09 to 6.34) | 3.49 (2.79 to 4.36)         | 1.83 (1.63 to 2.06) | 1.49 (1.32 to 1.68) |
| Prior opioid-related hospitalization  | No                            | Ref                | Ref                         | Ref          |
|                                       | Yes                           | 1.15 (1.02 to 1.30) | 1.12 (0.98 to 1.28)         | 1.33 (1.18 to 1.49) | 1.11 (0.98 to 1.25) |
| Prior stimulant use-related hospitalization | No                      | Ref                | Ref                         | Ref          |
|                                       | Yes                           | 0.83 (0.66 to 1.06) | 1.05 (0.82 to 1.34)         | 1.20 (0.96 to 1.49) | 1.07 (0.85 to 1.34) |
| Prior alcohol use-related hospitalization | No                        | Ref                | Ref                         | Ref          |
|                                       | Yes                           | 1.09 (0.96 to 1.24) | 1.06 (0.93 to 1.21)         | 1.31 (1.18 to 1.46) | 1.16 (1.04 to 1.30) |
| Prior experience of incarceration     | No                            | Ref                | Ref                         | Ref          |
|                                       | Yes                           | 0.76 (0.68 to 0.84) | 1.00 (0.89 to 1.12)         | 0.99 (0.93 to 1.06) | 1.02 (0.96 to 1.10) |
| **Index hospitalization characteristics** |                               |                    |                            |               |
| Era of hospitalization                | 2001 to 2006                   | Ref                | Ref                         | Ref          |
|                                       | 2007 to 2011                   | 1.25 (1.11 to 1.41) | 0.94 (0.83 to 1.07)         | 1.13 (1.04 to 1.23) | 1.02 (0.94 to 1.11) |
|                                       | 2012 to 2018                   | 1.64 (1.44 to 1.87) | 0.83 (0.72 to 0.96)         | 1.73 (1.60 to 1.87) | 1.33 (1.22 to 1.46) |
| Length of stay                        | Days (scaled)                 | 1.04 (1.02 to 1.06) | 1.02 (0.99 to 1.06)         | 1.03 (1.01 to 1.04) | 1.01 (0.99 to 1.04) |

(Continued)
related infection were 7.92 (95% CI 7.66 to 8.29) per 100 person-years exposed to OAT, and 8.45 (8.06 to 8.84) per 100 person-years unexposed to OAT.

Extended Kaplan–Meier survival curves for time to rehospitalization are presented in Fig 3. Cumulative hazard for rehospitalization in OAT treatment versus nontreatment periods was 3.7% versus 4.3% at 30 days, 6.0% versus 7.1% at 90 days, and 12.7% versus 14.4% at 365 days.

In the adjusted model, OAT was also associated with lower hazard of rehospitalization (aHR 0.89, 95% CI 0.84 to 0.96; Table 2).

Other analyses

Supplementary analyses. In a post hoc supplementary analysis, we explored associations between OAT and mortality or rehospitalization for injecting-related infections at different points in follow-up using period-specific hazard ratios (Table 3).

Table 2. (Continued)

| Variable                        | Levels | Unadjusted hazard ratio (95% CI) | aHR (95% CI)² | Unadjusted hazard ratio (95% CI) | aHR (95% CI)² |
|---------------------------------|--------|---------------------------------|---------------|---------------------------------|---------------|
| Discharge against medical advice| No     | Ref                             | Ref           | Ref                             | Ref           |
|                                | Yes    | 0.94 (0.81 to 1.10)             | 1.10 (0.94 to 1.28) | 1.41 (1.30 to 1.54) | 1.47 (1.34 to 1.60) |

¹Rehospitalization with injecting-related infection.
²Fully adjusted model includes all variables listed in the table.

Other analyses

Supplementary analyses. In a post hoc supplementary analysis, we explored associations between OAT and mortality or rehospitalization for injecting-related infections at different points in follow-up using period-specific hazard ratios (Table 3).

Sensitivity analyses. We conducted post hoc sensitivity analyses exploring the impact of alternative OAT exposure timing definitions. Changing our exposure definition to incorporate the 2 days following the end of the OAT episode (reduced from 6 days in the main analysis) demonstrated similar results for the association between OAT with all-cause mortality (aHR 0.51, 95% CI 0.46 to 0.57) and with rehospitalization (aHR 0.88, 95% CI 0.83 to 0.95). Extending the exposure period to incorporate 10 days following the end of the OAT episode also demonstrated similar results for mortality (aHR 0.72, 95% CI 0.65 to 0.80) and for rehospitalization (0.89, 95% CI 0.84 to 0.95).

We then conducted a post hoc sensitivity analysis for the mortality outcome, reconstructing the analytic sample only among participants who experienced hospitalization for injecting-related infection at a date following their first record of OAT. This sample was slightly smaller (n = 7,641). Compared to the main analysis, more participants (59%) had an active OAT permit at the time of discharge from their index hospitalization, and more follow-up time was exposed to OAT (59%). In the fully adjusted model in this smaller sample, OAT was also associated with lower hazard of all-cause death (aHR 0.56, 95% CI 0.51 to 0.62).

Table 3. Period-specific aHRs for associations between OAT and all-cause mortality or rehospitalization for injecting-related infections.

| Time since hospital discharge | Mortality outcome | Rehospitalization outcome |
|------------------------------|-------------------|--------------------------|
| Within first year            | 0.47 (0.40 to 0.55) | 0.83 (0.77 to 0.91)      |
| Year 2 to 3                  | 0.66 (0.54 to 0.81) | 0.87 (0.76 to 0.99)      |
| Year 4 to 6                  | 0.76 (0.58 to 0.98) | 1.10 (0.91 to 1.33)      |

Hazard ratios (with 95% CIs) are for OAT exposure in fully adjusted models for all covariates.
aHR, adjusted hazard ratio; CI, confidence interval; OAT, opioid agonist treatment.

https://doi.org/10.1371/journal.pmed.1004049.t003
Discussion
Among a large cohort of people with opioid use disorder who have been hospitalized with injecting-related bacterial or fungal infections, we found that OAT was associated with lower risk of mortality and of rehospitalization with these infections. Our findings of an association between OAT and lower risk of death among people with opioid use disorder are consistent with prior evidence. The magnitude of the association between OAT and lower rehospitalization risk was more modest, but we are not aware of other interventions shown to reduce risk of reinfection in this setting. Rates of death and rehospitalization remained high for this young cohort of patients, even among those exposed to OAT. Half of the sample were not prescribed OAT at the time of discharge from their initial infection-related hospitalization, and only 15% of these participants initiated OAT in the 3 months following. This suggests that OAT should be offered as part of a multicomponent treatment strategy for injecting-related infections, aiming to reduce death and reinfection.

Our findings on the benefits of OAT engagement for patients after injecting-related infection in Australia build on mixed evidence from US insurance claims databases with lower rates of OAT exposure and smaller sample sizes. One previous study, among patients with injecting-related infective endocarditis in Massachusetts, US, showed time-varying exposure to OAT or extended-release naltrexone (an opioid antagonist) after hospitalization was associated with reduced risk of death [40]. A study of patients with injecting-related infective endocarditis in a US nationwide commercial insurance claims database examined associations between buprenorphine or naltrexone within 30 days after hospital discharge and risk of rehospitalization; effect estimates were associated with wide CIs that could include both beneficial or harmful effects [39]. The sample was smaller than ours (768 participants), and less than 6% of patients were exposed to these medications during follow-up [39]. In another study analyzing patients with injecting-related skin and soft tissue infections in the same US insurance claims database, 5.5% were exposed to buprenorphine or naltrexone in 30 days following hospital discharge, and this was associated with lower risk of rehospitalization with skin and soft tissue infections at 1 year of follow-up [41]. In a retrospective chart review study of patients admitted to a Missouri, US, hospital with injecting-related bacterial or fungal infections, those who received OAT during their hospitalization and continued it at discharge were less likely to be readmitted for injecting-related infections [56]. Our findings offer more robust supportive evidence of the beneficial effects of OAT exposure following hospitalization with multiple types of injecting-related infections, a larger sample size, and higher rates of OAT exposure with more specific effect estimates.

In the present study, we identified larger effect estimates for associations between OAT use and mortality than for associations between OAT use and rehospitalization with injecting-related infections. Our findings of a large protective effect of OAT on mortality risk reduction are in keeping with prior research, including multiple observational studies showing protective effects on all-cause mortality, opioid overdose deaths, and multiple other specific causes of death (including suicide, cancer, alcohol related, and cardiovascular related) [23,57]. Future research should investigate associations between OAT and specific causes of death after hospitalization with injecting-related infections. We hypothesized several pathways through which OAT might reduce risks of recurrence of injecting-related infections, including reducing frequency of opioid injecting, improving healthcare contacts, and reducing the impacts of criminalization and violence, but we were unable to explore specific mechanisms in this study of administrative data [1,26]. People accessing OAT may still be at risk of injecting-related infections through several pathways, including ongoing injection opioid use while on OAT, suboptimal access to safe housing and harm reduction services (e.g., needle exchange and supervised
consumption sites) and by injecting stimulants. OAT is known to reduce risks of death even among people who continue to use nonmedical or criminalized opioids [58], who may still be at risk of injecting-related infections. More research is needed to understand how to further reduce risks of injecting-related infections for people both on and off OAT.

Despite the known benefits of OAT for mortality risk reduction, less than half of participants in our study had an active prescription for OAT at the time of discharge from their index hospitalization with injecting-related bacterial or fungal infections. Published rates of OAT engagement as part of discharge planning following hospitalization with injecting-related infections vary widely, including 8% in Boston, Massachusetts, US [31] and 81% in Saint John, New Brunswick, Canada [29]. Improving access to OAT requires clinical and regulatory changes, including improved education for health professionals, increasing the number of points of access and availability on-demand, facilitating multiple medication options, and decreasing out-of-pocket patient costs [59]. Infectious disease specialists should consider integrating OAT into their care of patients with injecting-related infections [29,60]. Addiction medicine physicians can be incorporated into multidisciplinary teams to help care planning for these patients [30]. The time period immediately following discharge from acute care hospitalization is a particularly dangerous time for people with opioid use disorder [61], and so hospital-based healthcare providers should offer OAT initiation and facilitate a seamless transition to ongoing, outpatient care [27,29,33,56]. Risks of death and rehospitalization remain high among people with opioid use disorder even when engaged in OAT. Addiction treatment should be considered as part of a multicomponent secondary prevention strategy that could include consideration of environmental determinants like housing and access to other harm reduction services [1,62].

Our study has some important limitations. First, the OATS study cohort does not include all people who inject opioids in NSW; only those who have accessed OAT at least once during the study period are eligible for linkage and inclusion. However, this has previously been estimated to include >75% of people with opioid use disorder in NSW [28] and, to our knowledge, our study includes the largest sample to date of people with opioid use disorder following hospitalization with injecting-related infections. Second, as this is a study of administrative healthcare data, we have no information on additional factors that may influence risk for these infections, including individual injecting practices, housing status, and access to needle exchange or supervised injection sites [1]. We had only limited information on other social determinants, aside from prior incarceration (reflecting experiences of criminalization and possible unsafe injecting technique while incarcerated) and Aboriginal or Torres Strait Islander status (reflecting experiences of cultural strengths as well as settler colonialism and structural racism) [1]. These covariates were treated as time fixed at baseline (i.e., not time varying); further research is needed to understand whether social exposures like incarceration have time-dependent effects on injecting-related infections. Third, we did not have reliable information on the dose received each day, so did not include OAT dosing information. Fourth, oral methadone and sublingual buprenorphine were the only OAT medications used in NSW during the study period, so we were unable to estimate the effects of other treatment and harm reduction modalities including slow-release oral morphine, injectable OAT (with diamorphine or hydromorphone), or the emerging practice prescribing a “safe supply” of pharmaceutical opioids to substitute for illicitly manufactured heroin or fentanyl [63].

Conclusions

Among people with opioid use disorder following hospitalization for injecting-related bacterial or fungal infections, use of OAT is associated with lower risk of death or rehospitalization with
injecting-related infections. Our findings suggest that patients with opioid use disorder and injecting-related bacterial or fungal infections can reduce their risk of death or reinfection by engaging in OAT. Clinicians, hospitals, and health systems should facilitate access to OAT and support engagement.

Supporting information

S1 RECORD-PE Checklist. RECORD-PE, REporting of studies Conducted using Observational Routinely collected health Data statement for PharmacoEpidemiology. (PDF)

S1 Table. ICD-10 codes to define infections of interest. (DOCX)

S1 Fig. DAG describing hypothesized relationships between primary exposure, covariates, and outcomes. Figure generated with Daggity.net software. Timing of variables generally goes from the left to right. Blue circle is outcome. Green circle is exposure. Red circles are ancestors of exposures and of outcomes. White circles are adjusted variables (in this case, through study design and selection criteria). Gray circles are unobserved variables (in this case, macroenvironmental influences on risk). DAG, directed acyclic graph. (DOCX)

Acknowledgments

Data were provided, and linkage was conducted by the NSW Ministry of Health, Centre for Health Record Linkage, and Bureau of Crime Statistics and Research. We also acknowledge the support and expertise of the OATS Study Aboriginal Advisory Group in reviewing this manuscript. The authors acknowledge the Registries of Births, Deaths and Marriages, the Coroners and the National Coronial Information System for enabling Cause of Death Unit Record File (COD URF) data to be used for this publication.

We thank the faculty and trainees in the Research in Addiction Medicine Scholars (RAMS) program and in the Fellows Immersion Training in Addiction Medicine (FIT) program for helpful feedback on the analysis plan.

Disclaimers

The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health and Social Care.

Author Contributions

Conceptualization: Thomas D. Brothers, Dan Lewer, Duncan Webster, Andrew Hayward, Louisa Degenhardt.

Data curation: Thomas D. Brothers, Dan Lewer, Nicola Jones, Samantha Colledge-Frisby, Louisa Degenhardt.

Formal analysis: Thomas D. Brothers, Dan Lewer.

Investigation: Thomas D. Brothers, Dan Lewer, Nicola Jones, Samantha Colledge-Frisby.

Methodology: Thomas D. Brothers, Dan Lewer, Nicola Jones, Samantha Colledge-Frisby, Michael Farrell, Matthew Hickman, Duncan Webster, Andrew Hayward, Louisa Degenhardt.
**Project administration:** Thomas D. Brothers, Nicola Jones, Michael Farrell.

**Resources:** Nicola Jones, Michael Farrell, Matthew Hickman, Louisa Degenhardt.

**Supervision:** Dan Lewer, Duncan Webster, Andrew Hayward, Louisa Degenhardt.

**Visualization:** Thomas D. Brothers, Dan Lewer.

**Writing – original draft:** Thomas D. Brothers.

**Writing – review & editing:** Thomas D. Brothers, Dan Lewer, Nicola Jones, Samantha Colledge-Frisby, Michael Farrell, Matthew Hickman, Duncan Webster, Andrew Hayward, Louisa Degenhardt.

**References**

1. Brothers TD, Lewer D, Bonn M, Webster D, Harris M. Social and structural determinants of injecting-related bacterial and fungal infections among people who inject drugs: protocol for a mixed studies systematic review. BMJ Open. 2021 Aug 9; 11(8):e049924. https://doi.org/10.1136/bmjopen-2021-049924 PMID: 34373309

2. Gomes T, Kitchen SA, Tailor L, Men S, Murray R, Bayoumi AM, et al. Trends in Hospitalizations for Serious Infections Among People With Opioid Use Disorder in Ontario, Canada. J Addict Med. 2021 Oct 28; Online Ahead of Print. https://doi.org/10.1097/ADM.0000000000000928 PMID: 34711742

3. Serota DP, Bartholomew TS, Tookes HE. Evaluating Differences in Opoid and Stimulant Use-Associated Infectious Disease Hospitalizations in Florida, 2016–2017. Clin Infect Dis. 2021 Oct 1; 73(7): e1649–57. https://doi.org/10.1093/cid/ciaa1278 PMID: 32886747

4. Meisner JA, Anesi J, Chen X, Grande D. Changes in Infective Endocarditis Admissions in Pennsylvania During the Opioid Epidemic. Clin Infect Dis. 2020; 71(7):1664–70. https://doi.org/10.1093/cid/ciz1038 PMID: 31630192

5. Lewer D, Freer J, King E, Larney S, Degenhardt L, Tweed EJ, et al. Frequency of healthcare utilisation by adults who use illicit drugs: a systematic review and meta-analysis. Addiction. 2020 Jun; 115 (6):1011–23. https://doi.org/10.1111/add.14892 PMID: 31705770

6. Kim JH, Fine DR, Li L, Kimmel SD, Ngo LH, Suzuki J, et al. Disparities in United States hospitalizations for serious infections in patients with and without opioid use disorder: A nationwide observational study. PLoS Med. 2020 Aug 7; 17(8):e1003247. https://doi.org/10.1371/journal.pmed.1003247 PMID: 32764761

7. Wright A, Otome O, Harvey C, Bowe S, Athan E. The Current Epidemiology of Injecting Drug Use-Associated Infective Endocarditis in Victoria, Australia in the Midst of Increasing Crystal Methamphetamine Use. Heart Lung Circ. 2018 Apr 1; 27(4):484–8. https://doi.org/10.1016/j.hlc.2017.03.166 PMID: 28533098

8. Mosseler K, Materniak S, Brothers TD, Webster D. Epidemiology, microbiology, and clinical outcomes among patients with intravenous drug use-associated infective endocarditis in New Brunswick. CJC Open. 2020; 2(5):379–85. https://doi.org/10.1016/j.cjco.2020.05.002 PMID: 32995392

9. Morin KA, Prevost CR, Elbl JK, Franklin MT, Moise AR, Marsh DC. A retrospective cohort study evaluating correlates of deep tissue infections among patients enrolled in opioid agonist treatment using administrative data in Ontario, Canada. PLoS ONE. 2020 Apr 24; 15(4):e0232191. https://doi.org/10.1371/journal.pone.0232191 PMID: 32330184

10. Meel R, Essop MR. Striking increase in the incidence of infective endocarditis associated with recreational drug abuse in urban South Africa. S Afr Med J. 2018 Jun 26; 108(7):585–9. https://doi.org/10.7196/SAMJ.2018.v108i13.1607 PMID: 30004347

11. Lewer D, Harris M, Hope V. Opiate Injection–Associated Skin, Soft Tissue, and Vascular Infections, England, UK, 1997–2016. Emerg Infect Dis. 2019 Sep 23; 23(8):1400–3. https://doi.org/10.3201/eid2508.170439

12. Wurcel AG, Anderson JE, Chui KKH, Skinner S, Knox TA, Snyderman DR, et al. Increasing Infectious Endocarditis Admissions Among Young People Who Inject Drugs. Open Forum Infect Dis. 2016 Jul 26; 3(3):ofw157. https://doi.org/10.1093/ofid/ofw157 PMID: 27800528

13. Barocas JA, Eltekhari Yazdi G, Savinkina A, Nolen S, Savitzky C, Samet JH, et al. Long-term Infective Endocarditis Mortality Associated With Injection Opioid Use in the United States: A Modeling Study. Clin Infect Dis. 2021 Dec 6; 73(11):ciaa1346. https://doi.org/10.1093/cid/ciaa1346 PMID: 32901815
14. McCarthy NL, Baggs J, See I, Reddy SC, Jernigan JA, Gokhale RH, et al. Bacterial Infections Associated With Substance Use Disorders, Large Cohort of United States Hospitals, 2012–2017. Clin Infect Dis. 2020 Oct 23; 71(7):e37–44. https://doi.org/10.1093/cid/ciaa008 PMID: 31905715

15. Cooper HLF, Brady JE, Ciccarone D, Tempalski B, Gostnell K, Friedman SR. Nationwide Increase in the Number of Hospitalizations for Illicit Injection Drug Use-Related Infective Endocarditis. Clin Infect Dis. 2007 Nov 1; 45(9):1200–3. https://doi.org/10.1086/522176 PMID: 17918083

16. Ronan MV, Herzig SJ. Hospitalizations Related To Opioid Abuse/Dependence And Associated Serious Infections Increased Sharply, 2002–12. Health Aff. 2016 Jan 5; 35(5):832–7. https://doi.org/10.1377/hlthaff.2015.1424 PMID: 27140989

17. Arora N, Panda PK, Cr P, Uppal L, Saroch A, Angrup A, et al. Changing spectrum of infective endocarditis in India: An 11-year experience from an academic hospital in North India. Indian Heart J. 2021 Nov 1; 73(6):711–7. https://doi.org/10.1016/j.ijh.2021.09.008 PMID: 34861981

18. Phillips KT, Stewart C, Anderson BJ, Liebschutz JM, Herman DS, Stein MD. A randomized controlled trial of a brief behavioral intervention to reduce skin and soft tissue infections among people who inject drugs. Drug Alcohol Depend. 2021 Feb 27;108646. https://doi.org/10.1016/j.drugalcdep.2021.108646 PMID: 33673753

19. Stein MD, Phillips KT, Herman DS, Keosaian J, Stewart C, Anderson BJ, et al. Skin-cleaning among hospitalized people who inject drugs: a randomized controlled trial. Addiction. 2021 May; 116(5):122–1130. https://doi.org/10.1111/add.15236 PMID: 32830383

20. Roux P, Donadille C, Magen C, Schatz E, Stranz R, Curano A, et al. Implementation and evaluation of an educational intervention for safer injection in people who inject drugs in Europe: a multi-country mixed-methods study. Int J Drug Policy. 2021 Jan 1; 87:102992. https://doi.org/10.1016/j.drugpo.2020.102992 PMID: 33096364

21. Robertson R, Broers B, Harris M. Injecting drug use, the skin and vasculature. Addiction. 2021 Jul; 116(7):add.15283. https://doi.org/10.1111/add.15283 PMID: 33051902

22. Harris M. Normalised pain and severe health care delay among people who inject drugs in London: Adapting cultural safety principles to promote care. Soc Sci Med. 2020 Sep 1; 260:113183. https://doi.org/10.1016/j.socscimed.2020.102992 PMID: 32682207

23. Stone J, Degenhardt L, Grebely J, Laney S, Altice FL, Smyrnov P, et al. Modelling the intervention effect of opioid agonist treatment on multiple mortality outcomes in people who inject drugs: a three-setting analysis. Lancet Psychiatry. 2022 Apr; 8(4):301–309. https://doi.org/10.1016/s2215-0366(20)30538-1

24. MacArthur GJ, Minozzi S, Martin N, Vickerman P, Deren S, Bruneau J, et al. Opiate substitution treatment and HIV transmission in people who inject drugs: systematic review and meta-analysis. BMJ. 2012 Oct 3; 345:e5945. https://doi.org/10.1136/bmj.e5945 PMID: 23088795

25. Harris RE, Richardson J, Frasso R, Anderson ED. Experiences with skin and soft tissue infections among people who inject drugs in Philadelphia: A qualitative study. Drug Alcohol Depend. 2018 Jun 1; 187:8–12. https://doi.org/10.1016/j.drugalcdep.2018.01.029 PMID: 2966746

26. Frank D. “I was not sick and I didn’t need to recover”: Methadone Maintenance Treatment (MMT) as a refuge from criminalization. Subst Use Misuse. 2018 Jan 28; 53(2):311–22. https://doi.org/10.1080/10826084.2017.1310247 PMID: 28704148

27. Brothers TD, Fraser J, Webster D. Caring for people who inject drugs when they are admitted to hospital. CMAJ. 2021 Mar 22; 193(12):E423–4. https://doi.org/10.1503/cmaj.202124 PMID: 33753366

28. Lewer D, Jones NR, Hickman M, Larney S, Ezard N, Nielsen S, et al. Risk of discharge against medical advice among hospital inpatients with a history of opioid agonist therapy in New South Wales, Australia: A cohort study and nested crossover-cohort analysis. Drug Alcohol Depend. 2021 May; 2012 Oct 3; 345:e5945. https://doi.org/10.1016/j.drugalcdep.2021.108646 PMID: 33677353

29. Brothers TD, Mosseler K, Kirkland S, Melanson P, Barrett L, Webster D. Unequal access to opioid agonist treatment and sterile injecting equipment among hospitalized patients with injection drug use-associated infective endocarditis. PLoS ONE. 2022 Jan 26; 17(1):e0263156. https://doi.org/10.1371/journal.pone.0263156 PMID: 35081174

30. Brothers TD, Webster D. Multidisciplinary infective endocarditis care teams should address substance use disorders and harm reduction services. Open Heart. 2018 Jan 3; 4(2). Available from: https://openheart.bmj.com/content/4/2/e000699.responses#multidisciplinary-infective-endocarditis-care-teams-should-address-substance-use-disorders-and-harm-reduction-services

31. Rosenthal ES, Karchmer AW, Theisen-Toupal J, Castillo RA, Rowley CF. Suboptimal Addiction Interventions for Patients Hospitalized with Injection Drug Use-Associated Infective Endocarditis. Am J Med. 2016 May; 129(5):481–5. https://doi.org/10.1016/j.amjmed.2015.09.024 PMID: 26597670

32. Nguemeni Tiako MJ, Hong S, Bin Mahmood SU, Mori M, Mangi A, Yun J, et al. Inconsistent addiction treatment for patients undergoing cardiac surgery for injection drug use-associated infective
endocarditis. J Addict Med. 2020 Dec; 14(6):e350–4. doi:10.1097/ADM.0000000000000710 PMID: 32732685

33. Marks LR, Munigala S, Warren DK, Liang SY, Schwarz ES, Durkin MJ. Addiction Medicine Consultations Reduce Readmission Rates for Patients With Serious Infections From Opioid Use Disorder. Clin Infect Dis. 2019 May 17; 68(11):1935–7. doi:10.1093/cid/ciy924 https://academic.oup.com/cid/article/68/11/1935/5142876 PMID: 30357363

34. Braithwaite V, Ti L, Fairbairn N, Ahmad K, McLean M, Harrison S, et al. Building a hospital-based addiction medicine consult service in Vancouver, Canada: the path taken and lessons learned. Addiction. 2021 Jul; 116(7):1892–900. doi:10.1111/add.15383 PMID: 3339073

35. Brothers TD, Fraser J, MacAdam E, Hickcox S, Genge L, O'Donnell T, et al. Implementation and evaluation of a novel, unofficial, trainee-organized hospital addiction medicine consultation service. Subst Abus. 2021; 42(4):433–7. doi:10.1080/08897077.2020.1856291 PMID: 33332248

36. Hyshka E, Morris H, Anderson-Baron J, Nixon L, Dong K, Salvalaggio G. Patient perspectives on a harm reduction-oriented addiction medicine consultation team implemented in a large acute care hospital. Drug Alcohol Depend. 2019 Nov 1; 204:107523. doi:10.1016/j.drugalcdep.2019.06.025 PMID: 31541875

37. Serota DP, Tookes HE, Hervera B, Gayle BM, Roeck CR, Suarez E, et al. Harm reduction for the treatment of patients with severe injection-related infections: description of the Jackson SIRI Team. Ann Med. 53 (1):1960–1968. doi:10.1080/07853890.2021.1993326 PMID: 34726095

38. Bassetti S, Hoffmann M, Bucher HC, Fluckiger U, Battegay M. Infections Requiring Hospitalization of Injection Drug Users Who Participated in an Injection Opiate Maintenance Program. Clin Infect Dis. 2002 Mar 1; 34(5):711–3. doi:10.1086/338867 PMID: 11807861

39. Barocas JA, Morgan JR, Wang J, McLoone D, Wurcel A, Stein MD. Outcomes Associated With Medications for Opioid Use Disorder Among Persons Hospitalized for Infective Endocarditis. Clin Infect Dis. 2021 Feb; 72(3):472–8. doi:10.1093/cid/ciaa006 PMID: 31960025

40. Kimmel SD, Walley AY, Li Y, Linas BP, Lodi S, Bernson D, et al. Association of Treatment With Medications to Understand and Predict Adverse Outcomes in Opioid Agonist Treatment: Protocol for the Opioid Agonist Treatment Safety (OATS) Study. BMJ Open. 2018 Aug; 8(8):e025204. doi:10.1136/bmjopen-2018-025204 PMID: 30082370

41. Larney S, Jones NR, Shanahan M, Dobbins T, Gissev N, et al. Using routinely collected data to understand and predict adverse outcomes in opioid agonist treatment: Protocol for the Opioid Agonist Treatment Safety (OATS) Study. BMJ Open. 2018 Aug; 8(8):e025204. doi:10.1136/bmjopen-2018-025204 PMID: 30082370

42. Larney S, Jones N, Fiellin DA, Nielsen S, Jones NR, et al. Using routinely collected data to understand and predict adverse outcomes in opioid agonist treatment: Protocol for the Opioid Agonist Treatment Safety (OATS) Study. BMJ Open. 2018 Aug; 8(8):e025204. doi:10.1136/bmjopen-2018-025204 PMID: 30082370

43. Langan SM, Schmidt SA, Wing K, Ehrenstein V, Nicholls SG, Filion KB, et al. The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE). BMJ. 2018 Nov 1; 363:k3532. doi:10.1136/bmj.k3532 PMID: 30429167

44. Suissa S. Immortal Time Bias in Pharmacoepidemiology. Am J Epidemiol. 2008 Feb 15; 167(4):492–9. doi:10.1093/aje/kwm324 PMID: 18056625

45. Therneau T, Crowson C, Atkinson E. Using Time Dependent Covariates and Time Dependent Coefficients in the Cox Model. Vienna, Austria: R Foundation; 2013 p. 31. Available from: https://cran.r-project.org/web/packages/survival/vignettes/timedep.pdf

46. Jones NR, Shanahan M, Dobbins T, Degenhardt L, Montebello M, Gissev N, et al. Reductions in emergency department presentations associated with opioid agonist treatment vary by geographic location: A retrospective study in New South Wales, Australia Drug Alcohol Review. 2019; 38(6):690–8. doi:10.1002/dar.12820 PMID: 32795883

47. Jones NR, Hickman M, Larney S, Nielsen S, Ali R, Murphy T, et al. Hospitalisations for non-fatal overdose among people with a history of opioid dependence in New South Wales, Australia, 2001–2018: Findings from the OATS retrospective cohort study. Drug Alcohol Depend. 2020 Oct 18; 108354. doi:10.1016/j.drugalcdep.2020.108354 PMID: 33121866

48. Degenhardt L, Larney S, Kimber J, Gissev N, Farrell M, Dobbins T, et al. The impact of opioid substitution therapy on mortality post-release from prison: retrospective data linkage study. Addiction. 2014 Aug 1; 109(8):1306–17. doi:10.1111/add.12536 PMID: 24612249
50. Degenhardt L, Randall D, Hall W, Law M, Butler T, Burns L. Mortality among clients of a state-wide opioid pharmacotherapy program over 20 years: Risk factors and lives saved. Drug Alcohol Depend. 2009 Nov 1; 105(1):9–15. https://doi.org/10.1016/j.drugalcdep.2009.05.021 PMID: 19608355

51. Kimber J, Larney S, Hickman M, Randall D, Degenhardt L. Mortality risk of opioid substitution therapy with methadone versus buprenorphine: a retrospective cohort study. Lancet Psychiatry. 2015 Oct 1; 2(10):901–8. https://doi.org/10.1016/S2215-0366(15)00366-1 PMID: 26384619

52. Cousins G, Teljeur C, Motterlini N, McCowan C, Dimitrov BD, Fahy T. Risk of drug-related mortality during periods of transition in methadone maintenance treatment: A cohort study. J Subst Abus Treat. 2011 Oct 1; 41(3):252–60. https://doi.org/10.1016/j.jsat.2011.05.001 PMID: 21696913

53. Pearce LA, Min JE, Piske M, Zhou H, Homayra F, Slaunwhite A, et al. Opioid agonist treatment and risk of mortality during opioid overdose public health emergency: population based retrospective cohort study. BMJ. 2020 Mar 31; 368:m772. https://doi.org/10.1136/bmj.m772 PMID: 32234712

54. Schultz LR, Peterson EL, Breslau N. Graphing survival curve estimates for time-dependent covariates. Int J Methods Psychiatr Res. 2002; 11(2):68–74. https://doi.org/10.1002/mpr.124 PMID: 12459796

55. Yadav K, Lewis RJ. Immortal Time Bias in Observational Studies. JAMA. 2021 Feb 16; 325(7):686–7. https://doi.org/10.1001/jama.2020.9151 PMID: 33591334

56. Marks LR, Muniga S, Warren DK, Liss DB, Liang SY, Schwarz ES, et al. A Comparison of Medication for Opioid Use Disorder Treatment Strategies for Persons Who Inject Drugs With Invasive Bacterial and Fungal Infections. J Infect Dis. 2020 Oct 1; 222(Supplement_5):S513–20. https://doi.org/10.1093/infdis/jiz516 PMID: 32877547

57. Santu T Jr, Clark B, Hickman M, Grebely J, Campbell G, Sordo L, et al. Association of Opioid Agonist Treatment With All-Cause Mortality and Specific Causes of Death Among People With Opioid Dependence: A Systematic Review and Meta-analysis. JAMA Psychiatry. 2021 Sep 1; 78(9):979–93. https://doi.org/10.1001/jamapsychiatry.2021.0976 PMID: 34076676

58. Stone AC, Carroll JJ, Rich JD, Green TC. One year of methadone maintenance treatment in a fentanyl endemic area: Safety, repeated exposure, retention, and remission. J Subst Abus Treat. 2020 Aug 1; 115:108031. https://doi.org/10.1016/j.jsat.2020.108031

59. Priest KC, McCarty D, Lovejoy TI. Expanding Access to Medications for Opioid Use Disorder: Program and Policy Approaches from Outside the Veterans Health Administration, J Gen Intern Med. 2020 Dec; 35(Suppl 3):886–90. https://doi.org/10.1007/s11606-020-06266-3 PMID: 33145685

60. Fanucchi LC, Walsh SL, Thornton AC, Nuzzo PA, Lofwall MR. Outpatient Parenteral Antimicrobial Therapy Plus Buprenorphine for Opioid Use Disorder and Severe Injection-related Infections. Clin Infect Dis. 2020 Mar 3; 70(6):1226–9. https://doi.org/10.1093/cid/ciz654 PMID: 31342057

61. Lewer D, Eastwood B, White M, Brothers TD, McCusker M, Copeland C, et al. Fatal opioid overdoses during and shortly after hospital admissions in England: case-crossover study. PLoS Med. 2021 Oct 5; 18(10):e1003759. https://doi.org/10.1371/journal.pmed.1003759 PMID: 34610017

62. Lennox R, Lamarche L, Martin L, O'Shea T, Belley-Coˆte E, Cvetkovic A, et al. The Second Heart Program—A multidisciplinary team supporting people who inject drugs with infective endocarditis: Protocol of a feasibility study. PLoS ONE. 2021 Oct 28; 16(10):e0256839. https://doi.org/10.1371/journal.pone.0256839 PMID: 34710094

63. Bonn M, Palayew A, Bartlett S, Brothers TD, Touesnard N, Tyndall M. Addressing the Syndemic of HIV, Hepatitis C, Overdose, and COVID-19 Among People Who Use Drugs: The Potential Roles for Decriminalization and Safe Supply. J Stud Alcohol Drugs. 2020 Sep 1; 81(5):556–60. https://doi.org/10.15288/jsad.2020.81.556 PMID: 33028466